Trial reportCritical care (London, England)2026
On-scene selective brain cooling in ventricular fibrillation cardiac arrest: pilot results from the PRINCESS2 randomised trial.
Trial report in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06025123 (Prehospital Resuscitation Intranasal Cooling Effectiveness Survival Study 2), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prehospital Resuscitation Intranasal Cooling Effectiveness Survival Study 2 (PRINCESS2)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough ischemia-reperfusion brain injury represents a major clinical problem after cardiac arrest, no neuroprotective treatment currently exists. The PRINCESS2 trial is designed to confirm previous findings, indicating that on-scene selective brain cooling using a portable trans-nasal cooling method improves complete neurological recovery after out-of-hospital cardiac arrest (OHCA) with initial shockable rhythms (e.g. ventricular fibrillation). This prespecified pilot phase aimed to assess protocol adherence and safety aspects for this early cooling strategy.
methodsThe prespecified pilot phase includes the first 100 patients in the main PRINCESS2 trial, an ongoing European multicentre trial enrolling 1,022 OHCA patients with initial shockable rhythm. Patients are randomised to intervention; trans-nasal cooling initiated at the scene of arrest followed by systemic hypothermia (33 ± 0.5 °C for 24 h) in the intensive care unit, or control; normothermia with fever control. Neuroprognostication and criteria for withdrawal of life-sustaining treatment are protocolised. Pilot outcomes were adherence to treatment allocation and protocol in the prehospital and in-hospital stages, and safety aspects, including 72-hour survival, prehospital re-arrest, device-related adverse events, and adverse events within 7 days such as bleeding, sepsis, arrhythmias with hemodynamic compromise, or need for circulatory support.
resultsIn total, 100 patients were randomised (median age 64 years, 91% male) to intervention (n = 50) or control (n = 50). All intervention patients received allocated treatment. Four had minor trans-nasal cooling interruptions, and two had systemic cooling interruptions. Among controls, 48/50 received allocated treatment, while two crossed over to cooling. One control was lost to follow-up. Overall, adherence to allocation and treatment protocol was 92%. Survival to 72 h was similar (intervention: 32/50 [64%], control: 31/49 [63%]) as well as prehospital re-arrest rates (11/49 [22%] vs. 9/40 [23%]). No device-related serious adverse events occurred. Adverse event rates within 7 days were similar.
conclusionIn this pilot phase of the PRINCESS2 trial, on-scene trans-nasal cooling in OHCA patients with shockable rhythms was performed with high protocol adherence without safety concerns. The main trial will continue as planned.
trial registrationClinicalTrials.gov: NCT06025123, registered Feb 1, 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.